BiVictriX Therapeutics PLC Result of AGM (8207G)

TIDMBVX

RNS Number : 8207G

BiVictriX Therapeutics PLC

31 March 2022

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Result of Annual General Meeting

Alderley Park, 31 March 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that at its Annual General Meeting, held today at 12.00pm, all resolutions were duly passed.

 
   For more information, please contact: 
     BiVictriX Therapeutics plc 
     Tiffany Thorn, Chief Executive Officer 
      Iain Ross, Chairman                       Email: [e-mail] 
 
     SP Angel Corporate Finance LLP (NOMAD     Tel: [phone] 
      and Broker)                               0470 
     David Hignell, Caroline Rowe (Corporate 
      Finance) 
      Vadim Alexandre, Rob Rees (Sales and 
      Broking) 
 
      Panmure Gordon (UK) Limited (Joint        Tel: [phone] 
      Broker)                                   2500 
     Rupert Dearden, Freddy Crossley, Emma 
      Earl 
                                                Tel: [phone] 
      Consilium Strategic Communications 
     Mary-Jane Elliott, Melissa Gardner,       Email: [e-mail] 
      Genevieve Wilson 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSDIFDFEESEID

(END) Dow Jones Newswires

March 31, 2022 09:59 ET (13:59 GMT)